DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 3385--------------------------------------------------
       Tolebrutinib
       By: agate Date: August 23, 2021, 12:37 am
       ---------------------------------------------------------
       Trials of tolebrutinib will move to phase 3, apparently. The
       abstract indicates that some of this trial's participants were
       people with relapsing secondary progressive MS, and that the
       phase 3 trial would include relapsing and progressive forms of
       MS.
       From PubMed (August 22, 2021)--"Safety and efficacy of
       tolebrutinib, an oral brain-penetrant PTK inhibitor, in
       relapsing multiple sclerosis: A phase 2b, randomised,
       double-blind, placebo-controlled trial":
  HTML https://pubmed.ncbi.nlm.nih.gov/34418400/
       #Post#: 3462--------------------------------------------------
       Tolebrutinib for all types of progressive MS
       By: agate Date: November 13, 2021, 1:16 am
       ---------------------------------------------------------
       This article is from Spherix Global Insights (November 4, 2021),
       a market intelligence firm. It is very badly written but it
       looks as if tolebrutinib may be the first ever MS drug that will
       be meant to treat all progressive forms of MS, including SPMS
       that isn't considered active. I do not know what PfMS means but
       am guessing that it stands for "progressive forms of MS."
  HTML https://bit.ly/3wOPH6X
       #Post#: 3463--------------------------------------------------
       Sanofi's BTK inhibitor tolebrutinib shows "promising" 
       MS data
       By: agate Date: November 14, 2021, 1:49 am
       ---------------------------------------------------------
       More on tolebrutinib in PharmaTime (October 13, 2021)--"Sanofi's
       BTK inhibitor tolebrutinib shows 'promising' long-term MS data":
  HTML https://www.pharmatimes.com/news/sanofis_btk_inhibitor_tolebrutinib_gains_promising_long-term_ms_data_1380733
       *****************************************************